Wednesday, October 05, 2016 9:12:20 AM
Quote
__________________________________________________________
Acadia Pharmaceuticals (NASDAQ:ACAD) has continue to drift down over the last week. Leerink Swann initiated the shares as a Market Perform with a $34 price target yesterday. However, the analyst did have some optimism in his notes ""We continue to believe that pimavanserin (NUPLAZID) is one of the most differentiated commercial stage assets in CNS and could be attractive to multiple potential buyers, including BIIB (MP) and AGN (OP). However, we are resuming coverage with a neutral view on the stock based on (1) our belief that the pimavanserin roll-out will be slow and steady, given the drug's high price tag and the intrinsic challenges associated with assisting high out-of-pocket cost for Medicare patients and (2) our caution surrounding the upcoming readout for pimavanserin in Alzheimer's Disease Psychosis {ADP}, for which we believe there exists at least some credit in the stock today."
Piper Jaffray is a bit more enthusiastic this morning as they reissue their Buy rating with a $44 price target. Its analyst notes that Nuplazid will probably have a slow rollout but should eventually garner near $1 billion in annual sales.
Acadia feels very much like Relypsa (NASDAQ:RLYP) did early this year. The company will have initial challenges moving from a development firm to a commercial one. The stock will also ebb & flow on every new buyout rumor or lack thereof. In the end, I think the company will share a similar fate with Relypsa that was bought out in July for a 60% premium although I don't see a deal until the first half of 2017 and the most logical suitor remains Biogen (NASDAQ:BIIB).
_____________________________________________
http://seekingalpha.com/article/4010277-biotech-forum-daily-digest-follow-progenics-dynavaxs-roller-coaster-week-spotlight-scynexis
ACAD
Recent ACAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 10:53:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 10:46:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/23/2024 09:14:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:34:29 PM
- Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals • Business Wire • 09/23/2024 08:15:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 08/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:43:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:40:42 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:39:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:37:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:35:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:33:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:31:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:29:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:27:51 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:25:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:23:55 PM
- Ryan Reynolds Announces More to Parkinson’s® Campaign • Business Wire • 08/14/2024 12:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 10:05:04 PM
- Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 08/07/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview • Business Wire • 08/06/2024 08:05:00 PM
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 • Business Wire • 07/24/2024 08:05:00 PM
- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med • Business Wire • 07/18/2024 01:04:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM